Aeolus Pharmaceuticl
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the… Read more
Aeolus Pharmaceuticl (AOLS) - Total Assets
Latest total assets as of June 2017: $794.00K USD
Based on the latest financial reports, Aeolus Pharmaceuticl (AOLS) holds total assets worth $794.00K USD as of June 2017.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aeolus Pharmaceuticl - Total Assets Trend (1996–2016)
This chart illustrates how Aeolus Pharmaceuticl’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aeolus Pharmaceuticl - Asset Composition Analysis
Current Asset Composition (September 2016)
Aeolus Pharmaceuticl's total assets of $794.00K consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 75.7% |
| Accounts Receivable | $750.00K | 18.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2016)
This chart illustrates how Aeolus Pharmaceuticl's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aeolus Pharmaceuticl's current assets represent 99.2% of total assets in 2016, an increase from 95.4% in 1996.
- Cash Position: Cash and equivalents constituted 75.7% of total assets in 2016, up from 55.0% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 18.0% of total assets.
Aeolus Pharmaceuticl Competitors by Total Assets
Key competitors of Aeolus Pharmaceuticl based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Aeolus Pharmaceuticl - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Aeolus Pharmaceuticl generates 0.50x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Aeolus Pharmaceuticl is currently not profitable relative to its asset base.
Aeolus Pharmaceuticl - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.30 | 7.04 | 0.54 |
| Quick Ratio | 1.30 | 6.58 | 0.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $175.00K | $ 4.15 Million | $ -1.05 Million |
Aeolus Pharmaceuticl - Advanced Valuation Insights
This section examines the relationship between Aeolus Pharmaceuticl's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.81 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 134.5% |
| Total Assets | $4.17 Million |
| Market Capitalization | $4.70K USD |
Valuation Analysis
Below Book Valuation: The market values Aeolus Pharmaceuticl's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aeolus Pharmaceuticl's assets grew by 134.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aeolus Pharmaceuticl (1996–2016)
The table below shows the annual total assets of Aeolus Pharmaceuticl from 1996 to 2016.
| Year | Total Assets | Change |
|---|---|---|
| 2016-09-30 | $4.17 Million | +134.50% |
| 2015-09-30 | $1.78 Million | -50.36% |
| 2014-09-30 | $3.58 Million | +82.10% |
| 2013-09-30 | $1.97 Million | +56.53% |
| 2012-09-30 | $1.26 Million | -45.15% |
| 2011-09-30 | $2.29 Million | -5.88% |
| 2010-09-30 | $2.43 Million | +200.00% |
| 2009-09-30 | $811.00K | -27.59% |
| 2008-09-30 | $1.12 Million | -42.00% |
| 2007-09-30 | $1.93 Million | -45.67% |
| 2006-09-30 | $3.55 Million | +279.30% |
| 2005-09-30 | $937.00K | -88.07% |
| 2004-09-30 | $7.86 Million | +627.41% |
| 2003-09-30 | $1.08 Million | -50.93% |
| 2002-09-30 | $2.20 Million | -74.46% |
| 2001-09-30 | $8.62 Million | +17.28% |
| 2000-09-30 | $7.35 Million | -8.15% |
| 1999-09-30 | $8.00 Million | -71.22% |
| 1998-09-30 | $27.80 Million | -27.79% |
| 1997-09-30 | $38.50 Million | -1.03% |
| 1996-09-30 | $38.90 Million | -- |